Spherix provides update on September 2014 request for inter parties review by VTech, and Uniden

Spherix Incorporated (SPEX) -- an intellectual property development company committed to the fostering and monetization of intellectual property, today provided an update on the September 2014 request for inter parties review by VTech Communications, Inc. and Uniden America Corporation. On March 3, 2015 the Patent Trial and Appeal Board ("Board") entered decisions instituting, on narrowly limited grounds, Inter Parties Review ("IPR") regarding a portion of the claims for two Spherix patents that are being asserted in litigation against VTech and Uniden. Other patents being asserted against VTech and Uniden are not affected by this IPR.

These decisions by the Board relate specifically and only to a portion of the claims asserted under U.S. Patent No. 5,581,599 and No. 6,614,899 and do not apply broadly to all claims under these patents nor to all of the Company's other claims of infringement asserted against VTech and Uniden.

In addition, the two patents affected by the IPR are not related to the patents involved in the litigations brought against Cisco, Verizon, Juniper, Huawei or T- Mobile.

Anthony Hayes, Chief Executive Officer of Spherix, stated, "We continue our relentless pursuit of remedies to the violation of intellectual property rights associated with our portfolio of technology patents. The Board's decisions affect a small portion of the claims we are asserting against VTech and Uniden and have no direct bearing on our claims against other companies or other litigation matters. We look forward to defending the merits of these patents in the upcoming IPR oral arguments, as well as the Federal Court case that is continuing against VTech and Uniden."

Source:

Spherix Incorporated

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.